MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-24-2026
Galapagos NV Cash and Cash Equivalents 2011-2026 | GLPG
Annual Cash and Cash Equivalents Galapagos NV
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 64.2 M | 167 M | 508 M | 2.23 B | 2.14 B | 1.86 B | 1.29 B | 1.15 B | 973 M | 340 M | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.23 B | 64.2 M | 1.07 B |
Quarterly Cash and Cash Equivalents Galapagos NV
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 2.23 B | - | 2.64 B | - | 2.14 B | - | 2.38 B | - | 1.86 B | - | 1.15 B | - | 1.29 B | - | 1.07 B | - | 1.15 B | - | 1.26 B | - | 973 M | - | - | - | 340 M | - | - | - | 188 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.64 B | 188 M | 1.44 B |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
75.2 M | $ 2.62 | 28.82 % | $ 147 M |  China |
 |
GlaxoSmithKline plc
GSK
|
3.87 B | $ 48.98 | 0.68 % | $ 173 B |  Britain |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K |  USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.51 | 7.34 % | $ 8.45 B |  Australia |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
Grifols, S.A.
GRFS
|
980 M | $ 9.25 | 1.49 % | $ 6.83 B |  Spain |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
89.4 M | - | - | $ 1.01 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
152 M | $ 25.92 | -0.86 % | $ 1.26 B | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
174 M | $ 24.45 | 4.49 % | $ 2.21 B | USA |
 |
Aptose Biosciences
APTO
|
6.15 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
48.4 M | - | - | $ 269 M | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
BioLineRx Ltd.
BLRX
|
10.4 M | $ 3.1 | 4.49 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
BioNTech SE
BNTX
|
9.76 B | $ 116.27 | -1.86 % | $ 27.2 B | Germany |
 |
Ascendis Pharma A/S
ASND
|
560 M | $ 235.41 | 2.95 % | $ 5 B |  Danmark |
 |
BioXcel Therapeutics
BTAI
|
29.9 M | $ 1.84 | 1.66 % | $ 4.66 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 9.74 | -1.37 % | $ 1.55 B | Britain |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | USA |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.66 | -1.85 % | $ 16.7 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
227 M | $ 67.49 | -3.02 % | $ 9.03 B | USA |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 4.51 | 8.41 % | $ 9.81 B | Israel |
 |
BeiGene, Ltd.
BGNE
|
2.63 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
144 M | - | -15.15 % | $ 60.3 M | Britain |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
21.8 M | - | -9.72 % | $ 5.89 M | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Coherus BioSciences
CHRS
|
103 M | $ 2.04 | 28.3 % | $ 192 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
2.38 B | $ 171.89 | -1.1 % | $ 25 B | USA |
 |
Bio-Path Holdings
BPTH
|
1.05 M | - | - | $ 100 K | USA |
 |
BioVie
BIVI
|
17.5 M | $ 1.2 | -3.7 % | $ 1.77 M | USA |